Insider Buying Persists as ProMIS Neurosciences Shares Dip Toward $3.43—Executives Signal Long‑Term Confidence in Neuro‑Therapeutic Pipeline

Insider Buying Continues Amid a Volatile Share Price

On November 4, 2026, owner Williams Eugene purchased 26,500 shares of ProMIS Neurosciences at $3.43 per share, bringing his stake to roughly 40,213 shares. The deal comes when the stock is trading at $3.65—a modest premium to the purchase price but still well below the 52‑week high of $27.40. Despite a steep decline of nearly 63 % year‑to‑date, the insider’s continued buying suggests confidence in the company’s long‑term prospects, especially as ProMIS moves closer to first‑in‑class antibody therapeutics for neurodegenerative disease.

What Does This Mean for Investors?

ProMIS’s market cap of $31.6 million and a price‑earnings ratio of –0.28 indicate that the company is still in the early, high‑risk stage of drug development. The latest insider purchase is a strong signal that management believes the valuation is currently undervalued. However, the stock’s recent 10‑week upside (over 10 %) is followed by a sharp 60 % monthly decline, underscoring the volatility that accompanies late‑stage biotech projects. Investors should weigh the insider’s bullish stance against the broader market’s skepticism, especially given the company’s limited commercial pipeline and reliance on future clinical milestones.

A Look at Williams Eugene’s Trading Pattern

Eugene’s transaction history shows a pattern of incremental buying rather than large, single‑trade infusions. Since the start of 2026, he has bought roughly 18,000 shares in four separate purchases—most recently in late October and early November—at prices ranging from $3.99 to $3.43. His most sizable single purchase was 11,000 shares on May 20, 2026, at a price of $0.00, reflecting an option exercise rather than a cash transaction. This disciplined, staged approach signals a long‑term commitment rather than a short‑term speculation. It also aligns with the company’s strategic milestones, such as upcoming conferences and clinical‑stage data releases, which may drive future valuation upside.

Broader Insider Activity Signals Confidence

The company’s other senior executives have also been buying shares. Notably, Chief Scientific Officer Neil Cashman purchased 10,000 shares at $3.86, and Chief Commercial Officer Ivana Rubino exercised a large option grant of 80,000 shares. These coordinated purchases suggest that key decision‑makers view the current price as an opportune entry point ahead of potential commercial or partnership developments. For investors, this collective insider optimism can be a bullish catalyst, particularly if ProMIS secures funding or regulatory approvals in the coming quarters.

Bottom Line for the Market

Eugene’s latest purchase—while modest in dollar terms—fits into a broader narrative of insider confidence during a period of significant stock volatility. For investors, the insider activity provides a useful barometer: if the company delivers on its clinical and commercial milestones, the stock could experience a substantial rebound. Conversely, continued setbacks could amplify the current price decline. In either case, the pattern of incremental insider buying remains a key indicator of the management team’s long‑term belief in ProMIS Neurosciences’ value proposition.